Swedish biotechnology company Cantargia AB (STO:CANTA) on Friday reported positive data from the ongoing phase I clinical trial of its second development programme, the antibody CAN10.

After reviewing unblinded data, the independent data monitoring committee recommended proceeding to the multiple dosing phase in psoriasis patients, scheduled to start in August 2024.

New biomarker data confirmed CAN10's potent inhibition of inflammatory immune cells after a single dose. The trial's first eight dose groups in healthy subjects have been completed without safety concerns, and the ninth group is initiating.

Biomarker analysis demonstrated a pronounced and long-lasting blockade of IL1RAP function after a single CAN10 dose.